Denali Therapeutics Inc. - Common Stock — Flux de trésorerie (NASDAQ:DNLI) | MetaTrader

Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques

Trimestriel Annuel

Flux de trésorerie liés aux activités d'exploitation 416.15 M-211.39 M-244.72 M-357.99 M-347.69 M-412.6 M -412.34 M Flux de trésorerie liés aux activités d'investissement -623.21 M-21.63 M-141.39 M249.31 M-88.76 M255.28 M 330.99 M Flux de trésorerie liés aux activités de financement 634.75 M19.35 M310.67 M17.82 M484.3 M189.22 M 412.02 M Flux de trésorerie disponible 416.15 M-211.39 M-244.72 M-357.99 M-347.69 M-422.1 M -419.23 M

Nouvelles

Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD?

Denali Therapeutics: 'Strong Buy' On AVLAYAH Approval And End Of 2026 FTD-GRN Data

Leqembi Isn’t Enough To Save Biogen Momentum (NASDAQ:BIIB)

Stocks Settle Higher on Iran Peace Hopes and Tech Strength

Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails

Stocks Climb on US-Iran Peace Hopes and Strength in Chipmakers

Stocks Supported by US-Iran Peace Deal Optimism

L’action Denali Therapeutics chute après l’échec d’un traitement contre Parkinson

DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects

Royalty Pharma T1 2026 : croissance à deux chiffres et prévisions relevées

Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform

DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?